WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced it has appointed Chris Chapman as chief commercial officer to lead its U.S. commercial organization and support global expansion efforts.
The company said Chapman will oversee commercialization of YCANTH, its treatment for molluscum contagiosum, and contribute to development strategy for additional pipeline candidates, including VP-315 for basal cell carcinoma and a Phase 3 program targeting common warts.
President and Chief Executive Officer Jayson Rieger said Chapman brings experience in dermatology product launches and commercial organization leadership.
Chapman most recently served as chief commercial officer at Dermavant Sciences, where he was involved in the launch of VTAMA cream for plaque psoriasis and atopic dermatitis. He also participated in the integration of Dermavant’s commercial operations with Organon following its acquisition of Dermavant in October 2024, according to the release.
Earlier in his career, Chapman served as vice president and general manager of the U.S. Prescription Business at Galderma and held commercial leadership roles at Pfizer.
Verrica is a dermatology-focused biopharmaceutical company developing and commercializing treatments for skin diseases requiring medical intervention. The company is headquartered in West Chester.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.